-
Patient BillingLearn moreNeoGenomics makes billing as flexible as possible by providing many different payment options. -
NeoGenomics Announces Participation in NCI-MATCH
Clinical TrialRead press release -
NeoGenomics Awarded Clinical Reference Laboratory Testing Services Agreement with PremierRead press release
-
New Posters from ASH 2017MDS Diagnosis, cfRNA and NGS, Liquid Biopsy for Myeloid Neoplasms, Clonal Hematopoiesis and MDS, and FLT3 Mutation in Acute Myeloid LeukemiaRead now
-
Global CapabilitiesLearn about our unique service offerings that are now available globallyRead now
-
New Research Paper in Journal of CancerA Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on BiopsyRead now
-
New Article in Springer NatureDetecting BRAF, KRAS, and EGFR Mutations via NGS vs. PCR-based KitsRead now
-
NeoGenomics Announces Expansion of Immuno-Oncology Profiling TestsRead press release
-
NeoGenomics Reports that its NeoLAB® Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate CancerRead press release
-
11q Aberration in NHLFISH for Burkitt-like lymphoma with 11q aberrationLearn more
-
ICOSFor diagnosis of T-cell lymphomas of follicular helper T-cell originLearn more
-
NGFRUseful in dx of brain tumors, MPNST, melanoma, and breast malignancyLearn more
-
11q Aberration in NHLFISH for Burkitt-like lymhoma with 11q aberrationLearn more
-
B-ALL MRD Flow PanelMinimal residual disease detection for treatment and prognosisLearn more